Johnson & Johnson (JNJ) Halts Development Of Botox Rival, Axes Staffers
4/14/2014 7:14:10 AM
Johnson & Johnson said on Friday it was ending its efforts to bring to market a rival drug to Allergan Inc's popular Botox anti-wrinkle treatment. J&J had acquired the drug, PurTox, with its 2009 purchase of Mentor, a leading maker of breast implants for cosmetic augmentation and reconstructive surgery. "After careful consideration, our Mentor business has decided to discontinue its neurotoxin program, commonly known as PurTox, in order to focus on its core breast surgery business, where we are an established leader and see greater opportunities to benefit patients and grow our business," J&J spokesman Thomas Sanford said in an emailed statement.
Help employers find you! Check out all the jobs and post your resume.
comments powered by